Novo Nordisk has launched Wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks. Priced between Rs 17,345 and Rs 26,050 per month, the injectable drug targets India’s large obese population. The company aims to create awareness and collaborate with stakeholders to combat obesity, citing its significant impact on India’s GDP.